RxDoctor Payments Data

Samantha Fraley, APRN

Primary Care · Prestonsburg, KYNPI 1780279166

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,993 of the $3,463 with a category attached, or 86.4%. It is spread thinly across 40 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations.

$3,463in general payments, 2019–2025

Across 159 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$357
  • Pfizer$301
  • Johnson & Johnson$288
  • Novartis$247
  • Bristol Myers Squibb$189
  • Shield Therapeutics Inc$168
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$2,99386%
  • Education$47014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,463 in reported general payments places this provider in the 85th percentile of 80 primary care providers in Kentucky.

See all primary care providers in Kentucky

Medicare billing

Part B allowed, 2024
$29,885
Medicare patients
136
Services billed
561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib14$229,758
Abiraterone Acetate26$127,090
Anastrozole77$845
Ondansetron OdtOndansetron46$810
Levothyroxine Sodium75$294
Potassium Chloride25$253
Letrozole23$155
Methylprednisolone12$108
Vitamin D2Ergocalciferol (Vitamin D2)40$104
Alendronate Sodium29$101
Megestrol Acetate11$72
Levofloxacin24$52
Amoxicillin18$51
Pantoprazole Sodium12$48
Prednisone21$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$120$229,75814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 80 primary care providers in Kentucky.

Other primary care in Prestonsburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →